Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 159

Results For "Business"

2467 News Found

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
News | January 24, 2023

Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%

The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility


Supriya Lifescience appoints Krishna Raghunathan as CFO
People | January 24, 2023

Supriya Lifescience appoints Krishna Raghunathan as CFO

He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group


SK bioscience appoints new executives
People | January 23, 2023

SK bioscience appoints new executives

Two biopharmaceutical experts join SK bioscience to strengthen the future strategies


Marksans Pharma raises Rs. 372.40 crores
News | January 21, 2023

Marksans Pharma raises Rs. 372.40 crores

OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.


Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
News | January 21, 2023

Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics

The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.


Innova Captab gets SEBI nod to raise funds via IPO
News | January 20, 2023

Innova Captab gets SEBI nod to raise funds via IPO

The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore


Blue Jet Healthcare gets SEBI nod for IPO
News | January 20, 2023

Blue Jet Healthcare gets SEBI nod for IPO

The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.


Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes
News | January 20, 2023

Cheplapharm selects Generis’ CARA Life Sciences platform to unify their clinical processes

Connectivity and harmonisation were both key driving factors behind our decision to choose the CARA Life Sciences Platform to consolidate our processes


Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | January 19, 2023

Stelis Biopharma’s flagship facility receives EIR from USFDA

The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes


Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets
News | January 18, 2023

Heart failure treatment becomes affordable with Glenmark launching Sacubitril + Valsartan tablets

Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)